US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

266.00

-13.0200-4.67%

Post-market: 264.12-1.8800-0.71%19:53 EDT

Volume:290.13K

Turnover:77.49M

Market Cap:498.61M

PE:- -

High:274.71

Open:269.37

Low:260.01

Close:279.02

52wk High:341.93

52wk Low:74.95

Shares:1.87M

Float Shares:1.87M

Volume Ratio:0.94

T/O Rate:15.48%

Dividend:1.00

Dividend Rate:0.38%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

PreAxia Health Care Delays Annual SEC Filing

Delhi High Court Orders Forensic Audit on Fortis Promoter Share Dissipation; No Liability on Company

Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says

MT Newswires Live

Sector Update: Healthcare Stocks Decline Monday Afternoon

MT Newswires Live

Alvotech Stock Gains After FDA Accepts for Review Crohn's Treatment AVT80

Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says

MT Newswires Live

Sunshine Lake Pharma Details Terms of New Healthcare-Focused Investment Fund

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)

Sector Update: Healthcare

MT Newswires Live

Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline

Karyopharm Seeks Accelerated FDA Approval for XPOVIO Combo

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNTech SE (BNTX)

Karyopharm submits sNDA to FDA for XPOVIO

Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY)

Humana Stock And 2 Healthcare Names Backing The Shift To Preventive Care

Simply Wall St.

Takeda Pharmaceutical Says US FDA Approves Rusfertide for Rare Type of Blood Cancer

MT Newswires Live

Advicenne Pulls U.S. Application for Rare Kidney Drug ADV7103 After FDA Feedback

PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/LABU/news?page=18"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":266,"timestamp":1789070400000,"preClose":279.02,"halted":0,"volume":290130,"hourTrading":{"tag":"盘后","latestPrice":264.12,"preClose":266,"latestTime":"19:53 EDT","volume":1904,"amount":504475.6573,"timestamp":1789084425326,"change":-1.88,"changeRate":-0.007068,"amplitude":0.00782},"delay":0,"changeRate":-0.046663321625689855,"floatShares":1874486,"shares":1874486,"eps":0,"marketStatus":"Not Yet Opened","change":-13.02,"latestTime":"09-10 16:00:00 EDT","open":269.37,"high":274.705,"low":260.01,"amount":77488111.8858,"amplitude":0.052666,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":279.02,"sharesOutstanding":3074486,"nav":278.651,"aum":522328218.83,"dividendRate":0.003776,"bidAskSpread":0.002964,"preHourTrading":{"tag":"盘前","latestPrice":268.99,"preClose":279.02,"latestTime":"09:29 EDT","volume":1828,"amount":503835.0052,"timestamp":1789046962415,"change":-10.03,"changeRate":-0.035947,"amplitude":0.054249},"postHourTrading":{"tag":"盘后","latestPrice":264.12,"preClose":266,"latestTime":"19:53 EDT","volume":1904,"amount":504475.6573,"timestamp":1789084425326,"change":-1.88,"changeRate":-0.007068,"amplitude":0.00782},"volumeRatio":0.944317,"impliedVol":0.9105,"impliedVolPercentile":0.502},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1874486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.944317,"shares":1874486,"dividePrice":1.0045,"high":274.705,"amplitude":0.052666,"preClose":279.02,"low":260.01,"week52Low":74.95,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":266,"eps":0,"divideRate":0.003776,"volume":290130,"delay":0,"ttmEps":0,"open":269.37,"prevYearClose":159.39,"prevWeekClose":303.55,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":311.81,"twentyDayClose":286.75,"sixtyDayClose":188.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:18,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664288388","title":"PreAxia Health Care Delays Annual SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2664288388","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664288388?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:17","pubTimestamp":1788207442,"startTime":"0","endTime":"0","summary":"PreAxia Health Care Payment Systems ( ($PAXH) ) has released a notification of late filing. PreAxia Health Care Payment Systems Inc. has filed a Fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/preaxia-health-care-delays-annual-sec-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/preaxia-health-care-delays-annual-sec-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","BK4581","BK4585","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664888875","title":"Delhi High Court Orders Forensic Audit on Fortis Promoter Share Dissipation; No Liability on Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888875","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888875?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:32","pubTimestamp":1788204734,"startTime":"0","endTime":"0","summary":"Fortis Healthcare Ltd. ( ($IN:FORTIS) ) has provided an announcement. Fortis Healthcare has disclosed that the Delhi High Court has ordered a foren...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/delhi-high-court-orders-forensic-audit-on-fortis-promoter-share-dissipation-no-liability-on-company?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/delhi-high-court-orders-forensic-audit-on-fortis-promoter-share-dissipation-no-liability-on-company?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XBI","XLV","BK4585","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000163","title":"Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000163","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000163?lang=en_us&edition=fundamental","pubTime":"2026-09-01 02:53","pubTimestamp":1788202412,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics  could have attractive commercial potential for Mimrylo following the US Food and Drug Administration's approval for treating polycythemia vera, a rare blood cancer, Truist Securities said in a note Monday.Mimrylo label's lack of a black-box warning, fatigue improvement and self-administration could support patient adoption, Truist said.The brokerage also expects payer approval given Mimrylo's potential to reduce the recurring burden of phlebotomies, while noting the treatment can be added to patients' existing PV therapy.Truist also expects Mimrylo to have three to four years of \"uncontested commercialization.\"Truist maintained a buy rating with a $170 price target.Price: 144.97, Change: +0.64, Percent Change: +0.44","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","PTGX","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664007127","title":"Sector Update: Healthcare Stocks Decline Monday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2664007127","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664007127?lang=en_us&edition=fundamental","pubTime":"2026-09-01 01:37","pubTimestamp":1788197856,"startTime":"0","endTime":"0","summary":"Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LLII","LU1232071149.USD","LU0471298777.SGD","LU0823434583.USD","IE00BKDWB100.SGD","LU1145028129.USD","IE0004445239.USD","LU1629891620.HKD","LU0456855351.SGD","LU0820562030.AUD","LU2746668974.SGD","LU0316494557.USD","GB00BDT5M118.USD","SGXZ81514606.USD","BK4599","CANC","LU1551013342.USD","LU2750360997.AUD","LU0417517546.SGD","LU0353189680.USD","WDNA","LU0345770993.USD","LU2089283258.USD","LU0266013472.USD","LU0466842654.USD","LU0882574139.USD","SG9999014880.SGD","IYH","LU0786609619.USD","LU1551013425.SGD","LU2237438978.USD","LU2602419157.SGD","LU0320765059.SGD","SG9999013999.USD","ELIL","LU2462157665.USD","LU2756315664.SGD","OZEM","LU1804176565.USD","LU1868836757.USD","LU0820561818.USD","IE00BN29S564.USD","LU1061106388.HKD","LU2361044949.HKD","LU1127390331.HKD","LU1712237335.SGD","LU0320765992.SGD","LU1974910355.USD","IE00BJJMRX11.SGD","LU1267930730.SGD","LU2236285917.USD","RXL","LLYX","LU0106261372.USD","ELIS","FTXH","XLV","LU2746668461.USD","SG9999015978.USD","LU1814569148.SGD","IE00B2B36J28.USD","SG9999017495.SGD","IE0009355771.USD","LU1280957306.USD","LU2552382215.SGD","IE00BFSS8Q28.SGD","LU0174119429.USD","LU2461242641.AUD","LU2471134796.USD","SGXZ57979304.SGD","TRUH","LU2168563687.JPY","LU1023059063.AUD","LU0354030511.USD","LU1720051108.HKD","LU2211815571.USD","LU2360106947.USD","LU0943347566.SGD","LU0133085943.USD","LU2361044865.SGD","IBB","LU0061475181.USD","LU1093756168.USD","LU2471134523.USD","LU2456880835.USD","LU0672654240.SGD","LU0354030438.USD","LU2491050071.SGD","LU0097036916.USD","IHE","LLYZ","LU0109391861.USD","BK4585","IE00BK4W5L77.USD","LU0109394709.USD","IE00BKPKM429.USD","LU2087625088.SGD","LU2417539215.USD","LU0820561909.HKD","MEDI","BK4534","LU2324357040.USD","FHLC","LU0964807845.USD","LLY","SGXZ31699556.SGD","IE00BJJMRZ35.SGD","LU0122379950.USD","BK4007","LU0158827948.USD","LU0432979614.USD","SG9999001176.USD","LU2237443622.USD","LU0058720904.USD","MEDX","LU1291159041.SGD","IE00B1BXHZ80.USD","LU0203202063.USD","LU2089284900.SGD","LU2264538146.SGD","SG9999018857.SGD","LU2462591350.SGD","LU2028103732.USD","LU0689472784.USD","AGNG","LU0225283273.USD","PPH","LU1548497426.USD","IE00BK4W5M84.HKD","SG9999015986.USD","LU0323591593.USD","LU1064131342.USD","IE00B1XK9C88.USD","LU1983299246.USD","LU1989771016.USD","SG9999014898.SGD","LU2271345857.HKD","LU0683600562.USD","LU0353189763.USD","IE00BFSS7M15.SGD","LU1988902786.USD","IE0005OL40V9.USD","LU0882574055.USD","LU2108987350.USD","LU2750360641.GBP","LU1069344957.HKD","SG9999014914.USD","BK4533","LU0345770308.USD","LU0889565916.HKD","LU1366192091.USD","LU2552382132.HKD","LU2265009873.SGD","LU0256863811.USD","IE00BJT1NW94.SGD","GDOC","LU2023251221.USD","LABU","LU2023250330.USD","LU2237443978.SGD","LU1868836591.USD","LU2237443895.HKD","SG9999018865.SGD","LU1057294990.SGD","LU2491050154.USD","LU0203201768.USD","LU0096364046.USD","LU2468319806.SGD","SG9999015952.SGD","ALVO","LU1323610961.USD","SG9999014906.USD","LU0114720955.EUR","IE0001KFT4U8.USD","IE00B7KXQ091.USD","LU0708995401.HKD","LU2237443549.SGD","LU2896262040.SGD","VHT","LU0234572021.USD","LU0158827781.USD","LU0006306889.USD","TMED","JDOC","LU2168564222.USD","LU0640476718.USD","LU1868837300.USD","PJP","LU0471298694.HKD","LU2168564495.EUR","LU2237443382.USD","LU2168564065.EUR","HRTS","LU1691799644.USD","SGXZ99366536.SGD","LU2357305700.SGD","SGXZ51526630.SGD","IE00BWXC8680.SGD","LU2552382058.USD","BK4139","IXJ","LU1093756325.SGD","LU2168564149.EUR","LU2237443465.HKD","IE00B4JS1V06.HKD","IE00BJLML261.HKD","LU1720051017.SGD","THNR","LU0079474960.USD","SG9999015945.SGD","LU2491049909.HKD","LU0823416689.USD","SG9999001176.SGD","LU0094547139.USD","LU0198837287.USD","LU2063271972.USD","IE00B4R5TH58.HKD","LU2471134952.CNY","LU2213496289.HKD","LU2089984988.USD","IE0002141913.USD","LU0385154629.USD","LU2023250504.SGD","IE00BJJMRY28.SGD","IE00BFTCPJ56.SGD","LU2756315318.SGD","LU1868836914.USD","IE00B775H168.HKD","LU0256863902.USD","BK4588","LU2106854487.HKD","IE0004445015.USD","LU2112291526.USD","XBI","LU1623119135.USD","LU2111349929.HKD","LU0289739699.SGD","BK4581","LU1917777945.USD","BK4516","CURE","LU0787776722.HKD","LU1035775433.USD","LU2471134879.HKD","LU1868837136.USD","LU2361045086.USD","ILDR","LU0210536198.USD","LU0238689110.USD","LU0823434740.USD","LU1979441026.SGD","MHIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664867007","title":"Alvotech Stock Gains After FDA Accepts for Review Crohn's Treatment AVT80","url":"https://stock-news.laohu8.com/highlight/detail?id=2664867007","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664867007?lang=en_us&edition=fundamental","pubTime":"2026-09-01 00:56","pubTimestamp":1788195360,"startTime":"0","endTime":"0","summary":"Shares of Alvotech rose after the Food and Drug Administration accepted for review a biologics license application for a potential biosimilar for an ulcerative colitis and Crohn's disease treatment.Th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK4139","ALVO","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663215001","title":"Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2663215001","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663215001?lang=en_us&edition=fundamental","pubTime":"2026-08-31 22:48","pubTimestamp":1788187693,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals (ARWR) thinks Plozasiran could receive US Food and Drug Administration approval to treat severe hypertriglyceridemia, or sHTG, by the second quarter of 2027, RBC Capital Mark","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNY","IE00BFXG1179.USD","ARWR","BK4588","BK4139","BK4007","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663800191","title":"Sunshine Lake Pharma Details Terms of New Healthcare-Focused Investment Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2663800191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663800191?lang=en_us&edition=fundamental","pubTime":"2026-08-31 22:37","pubTimestamp":1788187062,"startTime":"0","endTime":"0","summary":"The latest update is out from Sunshine Lake Pharma Co., Ltd. Class H ( ($HK:6887) ). Sunshine Lake Pharma has detailed the terms of a newly establi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sunshine-lake-pharma-details-terms-of-new-healthcare-focused-investment-fund?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sunshine-lake-pharma-details-terms-of-new-healthcare-focused-investment-fund?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XLV","BK4588","BK4581","LU0128526141.USD","XBI","LABU","HCSG","BK4137","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663700958","title":"Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663700958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663700958?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:50","pubTimestamp":1788184220,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vor Biopharma (VOR), Definium Therapeutics (DFTX) an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-definium-therapeutics-dftx-and-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-definium-therapeutics-dftx-and-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LABU","BK4007","XLV","BK4588","BK4585","HCSG","BK4137","VOR","XBI","LU0029874061.USD","DFTX","LU0128526141.USD","BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663200514","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2663200514","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663200514?lang=en_us&edition=fundamental","pubTime":"2026-08-31 21:04","pubTimestamp":1788181452,"startTime":"0","endTime":"0","summary":"Healthcare stocks were falling premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) down 0.6%.Arrowhead Pharmaceuticals' ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0128526141.USD","LABU","BK4137","BK4585","BK4139","HCSG","XBI","IBB","LU0029874061.USD","XLV","BK4581","ARWR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663009418","title":"Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2663009418","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663009418?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:30","pubTimestamp":1788179400,"startTime":"0","endTime":"0","summary":"Company views federal support for Schedule III as a significant evolution in U.S. cannabinoid policy and an important step toward a durable regulatory framework for cannabinoid-based medicines and wel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353300/0/en/endovia-health-sciences-welcomes-historic-shift-in-federal-cannabinoid-policy-advances-cannepil-fda-submission-and-expands-development-pipeline.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002521.SGD","LU0498741114.HKD","CBD","BK4588","LU0300736492.USD","LU0345780281.USD","LU0300736062.USD","LU0498741890.SGD","LU0788109121.HKD","THC","LU0368265764.SGD","LU0345780950.USD","LU0612318971.USD","B","LU0130103400.USD","LU0963586101.USD","SG9999001143.SGD","LU0648000940.SGD","LU1201861165.SGD","LU0330918003.SGD","LU2324357040.USD","BK4113","LU0630314457.HKD","BK4185","LU0612318385.USD","LU1023059493.AUD","BK4017","LU0055631609.USD","LU0075056555.USD","LU1430597077.USD","LU0654597011.USD","LABU","LU0724618789.USD","BU","BK4161","LU0496367417.USD","LU0345780521.USD","LU0788108826.HKD","LU0345781412.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663431003","title":"Karyopharm Seeks Accelerated FDA Approval for XPOVIO Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2663431003","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663431003?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:28","pubTimestamp":1788179295,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics ( ($KPTI) ) has shared an update. On August 31, 2026, Karyopharm Therapeutics Inc. said it has submitted a supplemental New...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/karyopharm-seeks-accelerated-fda-approval-for-xpovio-combo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/karyopharm-seeks-accelerated-fda-approval-for-xpovio-combo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663490008","title":"Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2663490008","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663490008?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177600,"startTime":"0","endTime":"0","summary":"BERKELEY HEIGHTS, N.J., Aug.  31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercial","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353242/0/en/kalaris-to-present-at-morgan-stanley-24th-annual-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","BK4588","XLV","LABU","LU0029874061.USD","LU0128526141.USD","BK4585","HCSG","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008480","title":"Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008480","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008480?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177600,"startTime":"0","endTime":"0","summary":"FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353254/0/en/cadrenal-therapeutics-announces-positive-outcome-from-fda-type-d-meeting-for-phase-3-registration-study-of-cad-1005-in-heparin-induced-thrombocytopenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","KD","BK4613","BK4528","IE00B7SZL793.SGD","BK4588","LENZ","BK4173","BK4139","BK4134","IE00B19Z4B17.USD","BK4023","SAP","HIT","IE00B66KJ199.SGD","BK4539","BK4585","IE0031619046.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008638","title":"Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNTech SE (BNTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008638?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:50","pubTimestamp":1788177029,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY), Lakefront Biotherapeutics (LKFT) and BioNT...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alnylam-pharma-alny-lakefront-biotherapeutics-lkft-and-biontech-se-bntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alnylam-pharma-alny-lakefront-biotherapeutics-lkft-and-biontech-se-bntx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTX","BK4585","XBI","BK4588","PBE","BK4551","LU0128526141.USD","BK4581","LU0114720955.EUR","LU0109394709.USD","LU0029874061.USD","BK4139","LABU","LU0889565916.HKD","BK4137","BK4548","BK4535","LU0882574055.USD","LU0320765992.SGD","GNMX","ALNY","LKFT","BK4568","HCSG","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663407048","title":"Karyopharm submits sNDA to FDA for XPOVIO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663407048","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663407048?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:36","pubTimestamp":1788176162,"startTime":"0","endTime":"0","summary":"Karyopharm (KPTI) Therapeutics announced that it has submitted a supplemental New Drug Application, sNDA, to the U.S. Food and Drug Administration,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/karyopharm-submits-snda-to-fda-for-xpovio-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/karyopharm-submits-snda-to-fda-for-xpovio-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KPTI","LABU","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079169","title":"Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663079169?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:30","pubTimestamp":1788168608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and Alnylam Pharma (ALNY) wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-boston-scientific-bsx-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-boston-scientific-bsx-alnylam-pharma-alny-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4504","XBI","IE00BFTCPJ56.SGD","LU0889565916.HKD","BSX","LU1989764748.USD","LU2491050071.SGD","IE0009355771.USD","GNMX","LU0345769631.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0128526141.USD","LU2362541513.USD","LU1989764664.SGD","LU1791710400.SGD","LU2506951958.HKD","LU2242649171.HKD","BK4585","PBE","XLV","LU2112291526.USD","HCSG","IE0002141913.USD","LU0114720955.EUR","BK4139","BK4548","LU1720051108.HKD","LU0048584097.USD","LU2506952170.USD","LU1720051017.SGD","LU0266013472.USD","ALNY","LU1718418525.SGD","LU2362540622.SGD","LU0225283273.USD","LU0353189763.USD","LU1804176565.USD","LU0320765992.SGD","LU1057294990.SGD","LU1989772840.SGD","LU2244417387.USD","BK4581","LABU","LU0138981039.USD","IE00B4R5TH58.HKD","LU0267386448.USD","LU0251132253.USD","LU1153585028.USD","LU0077335932.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077852","title":"Humana Stock And 2 Healthcare Names Backing The Shift To Preventive Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077852","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077852?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:25","pubTimestamp":1788168318,"startTime":"0","endTime":"0","summary":"Investors are watching a cultural pivot as more people question hyper quantified wellness and look for care that treats the whole person instead of just the data points. That shift could reshape where money flows across healthcare and wellness. Miss it and you could overlook companies that fit this mood. This article breaks down three stocks from our Holistic and Preventive Healthcare & Wellness Providers screener that appear closely tied to this news story.\nThe stocks highlighted below are a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-stock-and-2-healthcare-names-backing-the-shift-to-pre","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-stock-and-2-healthcare-names-backing-the-shift-to-pre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0128526141.USD","LU0320765489.SGD","HUM.AU","BK4588","LU1093756168.USD","LU0029874061.USD","HCSG","BK4196","BK6088","BK4137","BK4533","FXH","PRVA","LU1983260115.SGD","XBI","LU0170899867.USD","HUM","LU0238689110.USD","BK4566","BK7093","SG9999014013.SGD","IHF","XLV","SG9999014021.USD","Z4D.SI","LU0211331839.USD","SG9999014005.SGD","LU0266013472.USD","LU0208291251.USD","LABU","LU0256863811.USD","BK4539","LU0348723411.USD","BK7500","LU0390134368.USD","BK4581","LU0070302665.USD","LU1093756325.SGD","BK4154","BK6046","BK4585","LU0417517546.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663073421","title":"Takeda Pharmaceutical Says US FDA Approves Rusfertide for Rare Type of Blood Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2663073421","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663073421?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:24","pubTimestamp":1788164657,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical  said late Friday the US Food and Drug Administration approved rusfertide for the treatment of erythrocytosis in adults with polycythemia vera, a rare type of blood cancer.The approval is supported by data from a phase 3 study that showed rusfertide plus standard of care demonstrated higher response rate, including hematocrit control, reduced phlebotomy and improved fatigue compared with placebo plus standard of care, the company said.The treatment was generally well tolerated through 52 weeks, with injection-site reactions and anemia among the most common treatment-emergent adverse events, Takeda said.The approval does not change Takeda's consolidated financial guidance for fiscal 2026, it said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TAK","LABU","BK4585","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663022687","title":"Advicenne Pulls U.S. Application for Rare Kidney Drug ADV7103 After FDA Feedback","url":"https://stock-news.laohu8.com/highlight/detail?id=2663022687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663022687?lang=en_us&edition=fundamental","pubTime":"2026-08-31 13:38","pubTimestamp":1788154682,"startTime":"0","endTime":"0","summary":"Advicenne SA ( ($FR:ALDVI) ) has shared an announcement. Advicenne has voluntarily withdrawn its New Drug Application to the U.S. Food and Drug Adm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/advicenne-pulls-u-s-application-for-rare-kidney-drug-adv7103-after-fda-feedback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/advicenne-pulls-u-s-application-for-rare-kidney-drug-adv7103-after-fda-feedback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663024641","title":"PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663024641","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663024641?lang=en_us&edition=fundamental","pubTime":"2026-08-31 12:50","pubTimestamp":1788151819,"startTime":"0","endTime":"0","summary":"PharmaEssentia  has received approval from the US Food and Drug Administration for BESREMi  solution for injection in a pre-filled syringe of 500 mcg/mL and in a pre-filled pen injector 500 mcg/0.5 mL, according to a Friday filing to the Taiwan stock exchange.The company's shares were down 10% in Monday's trade.The drug is used in the treatment of adults with essential thrombocythemia and with polycythemia vera, or PV.Following the approval, PharmaEssentia USA Corporation will start the sales and marketing activities of BESREMi  for essential thrombocythemia in the US.The US FDA approved BESREMi  for the treatment of all adults with PV in November 2021.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":18,"totalSize":410,"code":"91000000","status":"200"}]}}